AMO Pharma Aligns with Global Regulators on cDM1 Clinical Trial Design

The company’s decision to prioritize hospitalization as the primary outcome measure follows six months of consultation with international health authorities. By focusing on this metric, AMO Pharma aims to address the significant clinical burden experienced by patients and caregivers navigating the complications of the disorder. Secondary assessments will track various functional markers to capture the condition’s diverse clinical presentation.

Dr. Mike Snape, CEO of AMO Pharma, noted that this regulatory consensus provides a clear mandate to accelerate the development program. The company intends to supplement these findings by surveying the patient community to better align study parameters with real-world disease impacts. Beyond the planned study, the organization is concurrently advancing AMO-02 as a treatment for Arrhythmogenic Right Ventricular Cardiomyopathy.

While this scientific advice marks a critical methodological milestone, it remains non-binding for future marketing applications. The company expects to announce the formal initiation of the study during the third quarter of 2026. Professor Hanns Lochmuller, a principal investigator at the Children's Hospital of Eastern Ontario, described the alignment as a vital development for a field that has historically lacked sufficient interventional research options for patients.